Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
Abstract Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relie...
Saved in:
Main Authors: | Hong-Bo Li, Zi-Han Yang, Qing-Qu Guo |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/406634dabe0244e6958f3f3e3ac6d2be |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in Pancreatic Ductal Adenocarcinoma Treatment
by: Eric M. Anderson, et al.
Published: (2021) -
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma
by: Iranzu González-Borja, et al.
Published: (2021) -
Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
by: Courtney T. Stump, et al.
Published: (2021) -
CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid‐derived suppressor cells
by: Haitao Gu, et al.
Published: (2021) -
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
by: Kostas Palamaris, et al.
Published: (2021)